Division of Interventional Cardiology, Henry Ford Hospital, Detroit, MI, USA.
Department of Structural Heart Disease, University of California-San Francisco, San Francisco, CA, USA.
Curr Cardiol Rep. 2022 Jun;24(6):679-687. doi: 10.1007/s11886-022-01691-8. Epub 2022 Mar 28.
The COVID-19 pandemic has created unprecedented challenges globally, with significant strain on the healthcare system in the United States and worldwide. In this article, we review the impact of COVID-19 on percutaneous coronary interventions and structural heart disease practices, as well as the impact of the pandemic on related clinical research and trials. We also discuss the consensus recommendations from the scientific societies and suggest potential solutions and strategies to overcome some of these challenges.
With the limited resources and significant burden on the healthcare system during the pandemic, changes have evolved in practice to provide care to the highest risk patients while minimizing unnecessary exposure during elective surgical or transcatheter procedures. The COVID-19 crisis has significantly impacted the management of patients with acute coronary syndromes, chronic coronary syndromes, and structural heart disease.
COVID-19 大流行在全球范围内带来了前所未有的挑战，使美国和全球的医疗体系承受了巨大压力。本文回顾了 COVID-19 对经皮冠状动脉介入治疗和结构性心脏病实践的影响，以及大流行对相关临床研究和试验的影响。我们还讨论了科学协会的共识建议，并提出了一些潜在的解决方案和策略，以克服其中的一些挑战。
在大流行期间，医疗资源有限，医疗系统负担沉重，实践中已经发生了变化，以便为高危患者提供护理，同时最大限度地减少择期手术或经导管程序期间的不必要暴露。COVID-19 危机对急性冠状动脉综合征、慢性冠状动脉综合征和结构性心脏病患者的管理产生了重大影响。
